The microenvironment in patients with PCa with pre-existing CVD is altered with distinct lymphocyte, monocyte, and inflammatory modulation, enabling GnRH antagonist treatment to potentially have beneficial effects in patients with pre-existing CVD over GnRHa [50]. The gene discussed is GNRH1; the disease is posterior cortical atrophy.